Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results

Replimune Group (NASDAQ:REPL) posted its earnings results on Monday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.03), FiscalAI reports.

Replimune Group Stock Performance

REPL opened at $11.63 on Monday. The company has a market capitalization of $960.32 million, a price-to-earnings ratio of -3.38 and a beta of 0.88. The business’s 50-day moving average price is $6.23 and its two-hundred day moving average price is $7.28. Replimune Group has a 1 year low of $1.50 and a 1 year high of $13.24. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.

Analyst Ratings Changes

Several analysts recently commented on REPL shares. Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research note on Friday, April 10th. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Wedbush raised their price target on Replimune Group from $2.00 to $6.00 and gave the stock a “neutral” rating in a research report on Monday, June 1st. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group has a consensus rating of “Reduce” and an average price target of $6.00.

Insider Buying and Selling at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the company. Invesco Ltd. grew its stake in shares of Replimune Group by 297.3% during the 4th quarter. Invesco Ltd. now owns 613,015 shares of the company’s stock worth $5,959,000 after acquiring an additional 458,714 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Replimune Group in the fourth quarter valued at approximately $322,000. Virtus Investment Advisers LLC lifted its position in shares of Replimune Group by 127.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company’s stock worth $254,000 after purchasing an additional 14,622 shares in the last quarter. SummitTX Capital L.P. bought a new stake in shares of Replimune Group in the fourth quarter worth $1,058,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in shares of Replimune Group in the fourth quarter worth $650,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.